Table 1.

Results of the GERAD+ study.

SNP	Closest Gene	CHR	MAF	Stage 1*			Stage 2†			Stage 3 ‡			Meta-analysis of GERAD+ Stage 1, 2 and 3 §			Meta-analysis of GERAD+ & ADGC
				P	OR	95% CI	P	OR	95% CI	P	OR	95% CI	P	OR	95% CI	P	OR	95% CI
rs3764650	ABCA7	19	0.10	2.6×10−7	1.22	1.13-1.32	1.9×10−5	1.28	1.14-1.44	2.9×10−7	1.22	1.13-1.32	4.5×10−17	1.23	1.18-1.30	5.0×10−21	1.23	1.17-1.28
rs610932	MS4A6A	11	0.42	1.8×10−8	0.88	0.85-0.92	1.6×10−3	0.90	0.84-0.96	2.1×10−5	0.91	0.87-0.95	1.8×10−14	0.90	0.87-0.92	1.2×10−16	0.91	0.88-0.93
rs670139	MS4A4E	11	0.41	1.0×10−5	1.11	1.06-1.16	1.1×10−3	1.11	1.04-1.19	3.2×10−3	1.06	1.02-1.11	1.4×10−9	1.09	1.06-1.12	1.1×10−10	1.08	1.06-1.11
rs3818361	CR1	1	0.19	3.2×10−12	1.21	1.14-1.27	1.4×10−3	1.14	1.05-1.23	NA	NA	NA	3.7×10−14	1.18	1.13-1.24	NA	NA	NA
rs744373	BIN1	2	0.29	1.5×10−10	1.17	1.11-1.22	3.8×10−5	1.17	1.08-1.25	NA	NA	NA	2.6×10−14	1.17	1.12-1.21	NA	NA	NA

CHR=Chromosome, MAF=Minor Allele Frequency in cases and controls.

^*GERAD1, EADI1, ADNI, & TGEN1 <6688 Cases, 13685 Controls.

^†GERAD2, deCODE, AD-IG: 4896 AD Cases, 4903 Controls.

^‡EADI2, CHARGE, Mayo2 <8286 AD Cases, 21258 Controls,

^§GERAD1&2, EADI1&2, ADNI, TGEN1, Decode, AD-IG, CHARGE, Mayo2 <19870 AD Cases and 39846 Controls